Solagran’s manufacturing partner Galenopharm is now free to commence production of Ropren for sale throughout Russia. Solagran is hopeful that initial production volumes will be sufficient to meet the needs of the main population centres of Moscow and St Petersburg.
Solagran will now turn its attention to ensuring that it is in a position to respond effectively to the significant world wide interest in this product. A plant containing the world’s first commercial polyprenols production facility is due to be opened shortly by the Governor of the Tomsk region. When operated at full capacity, this facility will generate sufficient polyprenols (Bioeffective R) to produce 50-60,000 courses of Ropren per annum.
These two events constitute a really major milestone for the company and mark the beginning of Solagran’s transition from a research-focused biotechnology company into an important player in the international natural pharmaceuticals market.